^
Association details:
Biomarker:KRAS G12C
Cancer:Cholangiocarcinoma
Drug:Krazati (adagrasib) (KRAS G12C inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Non Small Cell Lung Cancer)
New
Title:

Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Excerpt:
Mirati Therapeutics...announced the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) granted conditional marketing authorization approval for KRAZATI® (adagrasib) as a monotherapy indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRASG12C mutation and have progressive disease after prior therapy with, or intolerance to, platinum-based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy.
Evidence Level:
Sensitive: C3 – Early Trials
Title:

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation

Published date:
10/25/2020
Excerpt:
17% (3/18) of evaluable CRC patients had a confirmed objective response...Disease control was observed in 94% (17/18) of patients...Six patients in the other solid tumor cohort were evaluable for clinical activity. Confirmed partial responses (PRs) were observed in a patient with endometrial cancer and a patient with pancreatic cancer (n=1/1 each); unconfirmed PRs were observed in patients with ovarian cancer and CCA (n=1/1 each).
Trial ID: